IN8BIO Inc., a clinical-stage biopharmaceutical company, announced that its INB-200 clinical trial for glioblastoma patients has demonstrated significant clinical progress. A patient in the trial has surpassed four years without progression, marking a notable milestone in the treatment of front-line, grade IV glioblastoma. The company presented these positive results at the ASCO 2025 Annual Meeting, where it was reported that patients receiving multiple doses of INB-200 achieved a median progression-free survival of 16.1 months, notably longer than the 6.9 months typically observed with the standard-of-care Stupp protocol. Additionally, 40% of these patients remained progression-free for over 18 months with no significant toxicities observed. These findings highlight the potential of INB-200 to extend overall survival and provide durable therapy for glioblastoma patients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.